| pubmed-article:1980381 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1980381 | lifeskim:mentions | umls-concept:C0043474 | lld:lifeskim |
| pubmed-article:1980381 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1980381 | lifeskim:mentions | umls-concept:C0231220 | lld:lifeskim |
| pubmed-article:1980381 | lifeskim:mentions | umls-concept:C0259931 | lld:lifeskim |
| pubmed-article:1980381 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1980381 | pubmed:dateCreated | 1991-2-25 | lld:pubmed |
| pubmed-article:1980381 | pubmed:abstractText | Twenty-one immunodeficiency virus 1 (HIV 1)-positive hemophilic patients were treated with Azidothymidine (AZT) for symptomatic HIV infection. The median observation period was 20.5 months. At 25 months the probability of survival was 82%, the probability of progression of disease from CDC III or IV C2 to IV C1 (AIDS) was 20% in patients on continuous AZT treatment and 50% in patients with interruption of treatment. Three patients developed severe leukopenia and 3 patients severe anemia during AZT treatment. In 1 patient a dose-dependent striking increase of transaminases during AZT treatment was observed. In 7 patients treatment was interrupted, in 1 patient because of anemia, in 1 because of pruritus and in 5 patients because of non-compliance. No significant changes in the consumption of clotting factor concentrates and number of bleeding episodes before and during AZT treatment were noted. We conclude, that both hematological and non-hematological side effects of AZT in HIV 1-infected hemophilic patients are comparable to those seen in other risk groups. AZT does not increase the bleeding tendency in this patient group. | lld:pubmed |
| pubmed-article:1980381 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1980381 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980381 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1980381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980381 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1980381 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:1980381 | pubmed:issn | 0340-6245 | lld:pubmed |
| pubmed-article:1980381 | pubmed:author | pubmed-author:HartlHH | lld:pubmed |
| pubmed-article:1980381 | pubmed:author | pubmed-author:LechnerKK | lld:pubmed |
| pubmed-article:1980381 | pubmed:author | pubmed-author:KiffEE | lld:pubmed |
| pubmed-article:1980381 | pubmed:author | pubmed-author:SchweigerCC | lld:pubmed |
| pubmed-article:1980381 | pubmed:author | pubmed-author:PabingerII | lld:pubmed |
| pubmed-article:1980381 | pubmed:author | pubmed-author:SchwarzingerI... | lld:pubmed |
| pubmed-article:1980381 | pubmed:author | pubmed-author:KyrleP APA | lld:pubmed |
| pubmed-article:1980381 | pubmed:author | pubmed-author:EichingerSS | lld:pubmed |
| pubmed-article:1980381 | pubmed:author | pubmed-author:MayerhoferSS | lld:pubmed |
| pubmed-article:1980381 | pubmed:author | pubmed-author:StainCC | lld:pubmed |
| pubmed-article:1980381 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1980381 | pubmed:day | 13 | lld:pubmed |
| pubmed-article:1980381 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:1980381 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1980381 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1980381 | pubmed:pagination | 108-12 | lld:pubmed |
| pubmed-article:1980381 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:meshHeading | pubmed-meshheading:1980381-... | lld:pubmed |
| pubmed-article:1980381 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1980381 | pubmed:articleTitle | Azidothymidine (AZT) in the treatment of symptomatic HIV-1-infected hemophiliacs. | lld:pubmed |
| pubmed-article:1980381 | pubmed:affiliation | First Department of Medicine, University of Vienna, Austria. | lld:pubmed |
| pubmed-article:1980381 | pubmed:publicationType | Journal Article | lld:pubmed |
